secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001683168-23-001172
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma signs exclusive worldwide license with U. Arizona for PLpro COVID-19 treatment
--------------------------------------------------------------------------------

- License grants exclusive worldwide rights to PLpro protease inhibitors of SARS-CoV-2 (COVID-19).
- Company pays 3% royalty on net sales and 30% of sublicensee revenues.
- Milestone payments required; University can terminate if milestones not met.
- Collaboration began February 2022; option to license was exercised.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/0001683168-23-001172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-001172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer